• PN: B113287

COMPONENTS

45x Ab-conjugated beads (S5P3 - Human TNFRSF8 Ab-bead). PN: B113287A. One vial containing 100 µL of anti-Human TNFRSF8 conjugated to AimPlex Bead S5P3.

25x Biotin-detection Ab (Human TNFRSF8 Biotin-dAb). PN: B113287B. One vial containing 100 µL of biotinylated anti-Human TNFRSF8.

Lyophilized Standard Mix-Human Group 6, Panel B, 13-Plex. PN: HG62013. One vial containing lyophilized recombinant Eotaxin-2, IGFBP-1, IGFBP-7, MCP-4, MDC, MIP-1δ,  MIP-3α, MIP-3β, IL-6Rα, TNFRSF8, IL-1RII, Gp130, and TNFRII.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human TNFRSF8/sCD30. Can be multiplexed with other analytes in Human Group 6.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 10 pg/mL

Quantitation range:

LLOQ: < 20 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 1: Negligible

Sample volume: 15 µL/test

Description:

CD30, also known as TNFRSF8, is a cell membrane protein of the Tumor Necrosis Factor Receptor SuperFamily and a tumor marker. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells.

References:

1.      Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese) 34 (11): 711–5. PMID 16536313.

2.      Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology 22 (2): 319–24. doi:10.3892/ijo.22.2.319. PMID 12527929.

3.      Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research 19 (1): 22–7. doi:10.1158/1078-0432.CCR-12-0290. PMID 23155186.

.